ASN
AGRX

Advisory Services Network’s Agile Therapeutics AGRX Stock Holding History

Advisory Services Network’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,020
Closed -$3.94K – 3891
2023
Q4 		$3.94K Buy
+2,020
New +$4.06K ﹤0.01% 3190
2023
Q2 		– Sell
-1,630
Closed -$18.3K – 3962
2023
Q1 		$18.3K Hold
1,630
– – ﹤0.01% 2597
2022
Q4 		$18.5K Buy
1,630
+110
+7% +$1.28K ﹤0.01% 2533
2022
Q3 		$23K Buy
+1,520
New +$37.4K ﹤0.01% 1332
2022
Q1 		– Sell
-11
Closed -$10K – 1569
2021
Q4 		$10K Buy
+11
New +$15.5K ﹤0.01% 1395
2021
Q3 		– Hold
0
– – – 3489
2021
Q2 		– Hold
0
– – – 3677
2021
Q1 		– Hold
0
– -$1K – 3160
2020
Q4 		– Hold
0
– – – 3228
2020
Q3 		– Hold
0
– – – 3483
2020
Q2 		– Hold
0
– -$1K – 2934
2020
Q1 		– Hold
0
– – – 2973

Other funds holding AGRX

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Advisory Services Network's AGRX Position: Q1 2024 in Review

Advisory Services Network sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 2,020 shares — an estimated $3.94K sold.

Advisory Services Network first reported a position in AGRX in Q4 2021 and held it in 5 quarters. The position peaked at $23K in Q3 2022. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.

  • Advisory Services Network reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Advisory Services Network sold 2,020 Agile Therapeutics shares in Q1 2024, an estimated $3.94K.
  • Advisory Services Network first reported a position in Agile Therapeutics in Q4 2021 and held it in 5 quarters.
  • Advisory Services Network's Agile Therapeutics position peaked at $23K in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.

Based on Advisory Services Network's 13F filing for Q1 2024, filed 6 May 2024.